This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tilray (TLRY) Looks Good: Stock Adds 7.2% in Session
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Marijuana ETFs Bounce Back: Can the Rally Last?
by Sanghamitra Saha
Passing of a legalization bill by a U.S. congressional committee boosted the battered marijuana ETF space lately.
What's in the Cards for OrganiGram (OGI) in Q4 Earnings?
by Zacks Equity Research
According to OrganiGram (OGI), there is hugely unmet consumer demand for CBD products.
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth and Aurora Cannabis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth and Aurora Cannabis
Can Bill Hopes Relieve Earnings-Induced Pain in Pot ETFs?
by Sanghamitra Saha
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Implied Volatility Surging for Tilray (TLRY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Why Marijuana Stocks Plummeted in 2019
by Madeleine Johnson
Marijuana stocks were on a tear last year, but 2019 has sent stock tumbling back down to Earth. What happened?
Tilray, Inc. (TLRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of -72.41% and 3.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Trendy Earnings Charts
by Tracey Ryniec
Are cannabis and solar stocks still the place to be for traders in 2019?
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?
by Christopher Vargas
Tilray (TLRY) is set to report its third quarter results after the closing bell Tuesday, November 12.
U.S.-China Trade Progress, Q3 Earnings Results & Buy Yeti Stock - Free Lunch
by Benjamin Rains
The latest U.S.-China trade war news that could see the world's two largest economies roll back tariffs. Q3 earnings results from the likes of Qualcomm and Square. And why Yeti is a Zacks Rank #1 (Strong Buy) stock...
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.
Pay Attention to Hard to Borrow Rates, Even in Options Trades
by David Borun
The prices of traditional options strategies change along with interest rates
Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?
by Benjamin Rains
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
4 Highly-Ranked Cheap Stocks Trading Under $10 to Buy Right Now
by Benjamin Rains
Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank #2 (Buy) or better that investors might want to consider buying right now...
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $22.43 in the latest trading session, marking a +1.49% move from the prior day.
Tilray, Inc. (TLRY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Tilray, Inc. (TLRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $22.21, moving +0.27% from the previous trading session.
5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now
by Benjamin Rains
Today we found 5 cheap stocks currently trading for under $20 per share using our Zacks Stock Screener that investors might want to buy heading into November...
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.
Stocks Fall on U.S. Blacklist, China & the NBA and Buy Roku - Free Lunch
by Benjamin Rains
A look at the new U.S. blacklist on nearly 30 Chinese companies and how it might impact the upcoming trade talks. A dive into the dispute between the NBA and China, marijuana stocks, and why Roku is a Zacks Rank #1 (Strong Buy) - Free Lunch
Outlook for Alcohol Industry Dim on Soft Beer Sales & Tariffs
by Zacks Equity Research
Beer brands are struggling due to industry-wide softening of volumes. But, the industry can revive on product innovation, premiumization, use of natural ingredients and cannabis-infused drinks.
Is Constellation Brands (STZ) Stock a Buy Heading into Q2 Earnings?
by Benjamin Rains
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $26.71, marking a +0.41% move from the previous day.